IntroductIon
Hypertension is the leading modifiable cause of cardiovascular disease morbidity and mortality worldwide and disproportionately affects Blacks.
1,2 Shared decision making (SDM) has increasingly become appreciated as a method to enhance patient involvement in health care decisions, patient-provider communication, and patient-centered care. 3 While many definitions of SDM exist, it can broadly be described as a process by which patients and health care professionals work together to make health care decisions based on the best available clinical evidence and the patient's values and preferences. 4 The 2017 American College of Cardiology/American Heart Association Blood Pressure (BP) Clinical Practice Guideline notes that, "Adherence to recommendations can be enhanced by shared decision making between clinicians and patients, with patient engagement in selecting interventions on the basis of individual values, preferences, and associated conditions and comorbidities." 5 Moreover, the US Preventive Services Task Force (USPSTF) recommends that primary care practitioners screen for high BP in adults aged >18 years (grade A rec- Shared decision making (SDM) has increasingly become appreciated as a method to enhance patient involvement in health care decisions, patient-provider communication, and patient-centered care. Compared with cancer, the literature on SDM for hypertension is more limited. This is notable because hypertension is the leading risk factor for cardiovascular disease and both conditions disproportionately affect certain subgroups of patients. However, SDM holds promise for improving health equity by better engaging patients in their health care. For example, many reasonable options exist for treating uncomplicated stage-1 hypertension. These options include medication and/ or lifestyle changes such as healthy eating, physical activity, and weight management. Deciding on "the best" plan of action for hypertension management can be challenging because patients have different goals and preferences for treatment. As hypertension management may be considered a preference-sensitive decision, adherence to treatment plans may be greater if those plans are concordant with patient preferences. SDM can be implemented in a broad array of care contexts, from patient-provider dyads to interprofessional collaborations. In this article, we argue that SDM has the potential to advance health equity and improve clinical care. We also propose a process to evaluate whether SDM has occurred and suggest future directions for research. 10 Moreover, the prevalence of BP control was lower in Hispanic (45%), non-Hispanic Black (44.6%), and non-Hispanic Asian adults (37.4%), compared with nonHispanic White adults (50.8%). 10 Newer models of SDM recognize that patient preferences should play a key role in decision making and that final health care decisions should reflect patient preferences. 11 Racial/ ethnic differences in treatment preferences have been established across various health conditions; however, the association between patient preferences and health disparities is less clear. 12, 13 Moreover, little is known about the impact of preference concordance on adherence to treatment plans for hypertension. It is possible that preference concordance is less common in the groups most affected by health inequities (eg, racial/ethnic minorities) and thus, may partially explain suboptimal BP control.
Although not typically conceptualized as a preference-sensitive decision, we argue that hypertension management is well-suited for SDM because many reasonable pharmacological and non-pharmacological treatment options exist, 5, 14 and each option has different trade-offs, risks, and quality of life implications that may be valued differently by patients (Table 1) . For example, some hypertension-related decisions may have physical (medication side effects), psychological (health anxiety from constant tracking of BP and/ or behaviors), emotional (fear of falling due to polypharmacy) and/or financial (cost of medications and/or lifestyle interventions) consequences. Moreover, these consequences may differentially affect certain patient subgroups and thereby affect adherence to treatment plans.
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ExamplEs of HypErtEnsIon-rElatEd sdm IntErvEntIons
Compared with cancer, the literature on SDM in hypertension is more limited. [18] [19] [20] This may be due, in part, to the fact that hypertension management is dynamic and often involves a series of decisions made over months or years, whereas some cancer-related decisions are discrete and made within weeks or months (eg, mastectomy vs a lumpectomy with radiation for women with early stage breast cancer).
Nevertheless, there is evidence 24 and medication adherence. 25 For example, Olomu et al evaluated the impact of a SDM intervention on BP control in 243 patients recruited from two federally qualified health centers in Michigan. 21 The intervention included a physician training, patient activation session, and 1-page checklist used during primary care visits. They found that BP control was greater at six months for patients in the intervention site compared with the control site (OR=2.92, CI: 1.11-7.79). Hanlin et al evaluated hypertension control for 714 underserved patients (49.9% Medicaid and 50.2% Black) at a family medicine clinic in South Carolina using the "Measure Accurately, Act Rapidly, and Partner With Patients (MAP)" protocol. 22 The 'Partner with Patients' aspect involved SDM, discussions about affordable medications, BP self-monitoring, and reducing pill burden. They found that BP control increased from 61.2% to 89.9% (P<.0001) between baseline and the last study visit. The MAP protocol was further evaluated in 16 family medicine clinics. In hypertensive adults with complete baseline and 6-month visit data (N=16,787), BP control improved from 64.4% at baseline to 74.3% (P<.001) at 6 months and 73.6% (P<.001) at 12 months. 23 More broadly, Margolis et al explored the impact of a home BP telemonitoring with pharmacist case management intervention to improve BP control compared with usual care. The sample included 450 patients from 16 primary care clinics in Minnesota. 8 Overall, intervention group patients had better BP control over time. For example, at 18 months, BP control was observed in 71.8% of patients in the telemonitoring intervention group compared with 57.1% of patients in the usual care group (P =.003)
ImplEmEntIng sHarEd dEcIsIon makIng In dIffErEnt contExts
Given the dynamic nature of hypertension management and growing trend toward team-based care, 26 there are emerging models for how hypertension-related SDM could be realized in the future. For example, Project ACTIVE tested the effectiveness of a clinical intervention to personalize and prioritize USPSTF grade A or B preventive care recommendations for non-pregnant women. 27 Patients were recruited from a busy inner-city ambulatory care clinic in New York (N=140); the study involved six study visits over nine months. The two main outcomes were estimated gains in life expectancy (based on a validated mathematical model) and changes in unfulfilled clinical goals. Personalized graphical displays of estimated health gains from adherence to preventive care guidelines were generated for patients in the intervention group. A nurse practitioner communicated results to intervention patients and engaged them in an SDM process to identify and prioritize the preventive health goals they wanted to achieve. Subsequently, a health coach met with patients to set personalized action steps aligned with their goals and to be completed by the next study visit. Overall, intervention patients had an average of 21.04 months estimated gain in life expectancy compared with 4.52 months estimated gain in life expectancy for control patients. Project ACTIVE appears to be providing its benefit by improving control of hypertension and other key outcomes (eg, hyperlipidemia).
Other established SDM strategies may also be informative for hypertension management. 11, 28, 29 For example, Elwyn's Three Talk Model may be helpful for dyads (eg, physician-patient, nurse-patient, pharmacist-patient).
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"Team talk" refers to the importance of making patients aware of their choices and eliciting their goals to guide the decision making process. "Option talk" compares the various alternatives (eg, antihypertensive medication, lifestyle, or do nothing) by using risk communication principles. "Decision talk" is the task of coming to a decision that reflects the patient's informed preferences. Question prompt lists such as those developed by Irwig may also be useful for guiding conversations. 30 These questions include: 1) What will happen if I wait and watch? 2) What are my test or treatment options? 3) What are the benefits and harms of these options? 4) How do the benefits and harms weigh up for me? and 5) Do I have enough information to make a choice?
EvaluatIng sHarEd dEcIsIon makIng
While content expertise in the decision sciences is recommended to formally evaluate SDM interventions, measures and instruments
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already exist to help guide practitioners. 31, 32 In Figure 1 , we provide a thumbnail sketch for one of many potential approaches for evaluating SDM. Admittedly, there are challenges to implementing SDM in clinical care. 33, 34 One challenge is that some believe that SDM takes too much time and cannot be done during a typical clinical visit. While several studies have shown that SDM visits are not significantly longer than standard clinical care visits, 35 evaluations of brief SDM interventions for hypertension management that can be implemented in real world settings are needed to confirm efficacy and maximize clinician uptake. Another challenge is that SDM for chronic care management is not reimbursed (as opposed to other contexts like lung cancer screening). 36, 37 Consequently, scheduling longer follow up visits for the subset of hypertensive patients who may need more time for SDM will be challenging in the typical 15-minutes per patient context.
futurE dIrEctIons
Despite challenges with implementation, research opportunities remain for SDM in hypertension. First, it will be important to determine whether patients vary in their preferences regarding optimal BP management strategies. Second, evaluating whether patient preferences for SDM strategies differ by sociodemographic factors is needed to tailor future interventions. Third, a better understanding of clinician most affected by hypertension. Fifth, the potential role of telemedicine for enhancing SDM warrants more attention. Finally, more research is needed regarding novel uses of the electronic medical record for facilitating and documenting the SDM process with hypertensive patients.
conclusIons
Optimal hypertension management should be recognized as involving preference-sensitive decision making. Adherence to hypertension treatment plans are typically poor and it would be expected that more optimal adherence would be realized in plans that are concordant with patient preferences. SDM has the potential to advance health equity by better engaging patients in health care decisions and integrating patient preferences into treatment plans. SDM in hypertension may also improve patient-provider communication and in turn, strengthen partnerships between patients and various members of the health care team.
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The authors thank the National Heart, Lung, and Blood Institute for career development support of the first author (1 K01 HL135467-01), which helped facilitate the development of this manuscript. preferences for BP management and SDM strategies may have implications for adoption of SDM interventions. Fourth, while the potential for SDM interventions to reduce health inequalities has been explored broadly, 38 more research is needed on the efficacy of hypertension-specific interventions designed for the groups
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